Zevra Therapeutics

ZEVRA THERAPEUTICS INC

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Zevra Therapeutics Inc

Health Care

Press Releases

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

News

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Earnings

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

General

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

ZVRA

Aurora Cannabis

Alumis

ALT5 Sigma

Aquestive Therapeutics, Inc. - Common Stock

Aquestive Therapeutics

Arvinas

Canopy Growth Corporation - Common Shares

Canopy Growth

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Evolus

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals

Fulcrum Therapeutics, Inc. - Common Stock

Fulcrum Therapeutics

High Tide

LB Pharmaceuticals

MBX Biosciences

Mind Medicine (MindMed) Inc. - Common Shares

Mind Medicine

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Omeros

scPharmaceuticals

Septerna

SIGA Technologies

SNDL

Theravance Biopharma, Inc. - Ordinary Shares

Theravance Biopharma

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharma

Tvardi Therapeutics

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology

JMP Securities

Cantor Fitzgerald

HC Wainwright & Co.

Canaccord Genuity

Guggenheim

Comments

Zevra Therapeutics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO